- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- U.S. investors
- Regulated information in France
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Empowering Life
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Ethics and transparency
- Preserving the environment
You are here:
- Corporate Responsibility
Partnerships to improve access to healthcare
At Sanofi, we believe that everyone has the right to appropriate healthcare. Finding innovative solutions to improve access to medicines, vaccines and therapies is the area where our stakeholders expect the most from the pharmaceutical industry — and where we face our biggest challenge. The issues are complex and require cross-collaboration across sectors. For this reason, we combine our expertise with that of partners in the public, private and not-for-profit sectors. For example:
- We have renewed our partnership with the World Health Organization (WHO) to combat Neglected Tropical Diseases (NTDs). For the period 2001-2020, Sanofi’s commitment will represent USD 100 million in financial support and drug donations.
Since we launched our collaboration with the WHO in 2001 to combat sleeping sickness:
- over 34 million people have undergone screening since the start of the program1;
- about 200,000 patients have been treated for the disease, which is fatal if not treated in a timely manner;
- we have signed the London Declaration on NTDs alongside our public and private sector partners, with the explicit goal of controlling, eliminating or finding treatment solutions for 10 NTDs by 2020.
We have set up a public-private partnership (PPP) with the Drugs for Neglected Diseases Initiative (DNDi) to develop and manufacture an antimalarial drug adapted to WHO recommendations.
In partnership with the International Diabetes Federation and the Public Health Foundation of India, we combat pediatric diabetes with the KiDS initiative.
Through our “Healthy Children, Happy Children” program, we are committed to offering children the most innovative and adapted medicines and to improve access to these products worldwide, especially in emerging countries. Our approach is in line with the Children’s Rights and Business Principles, developed by Save the Children, UNICEF, and the UN Global Compact.
- WHO data, 2017